Elan, Eisai To Pay $214M Over Zonegran Marketing
The U.S. government has finalized a $203.5 million criminal and civil settlement with Irish drugmaker Elan Corp. PLC over off-label marketing of epilepsy drug Zonegran, as well as revealed an $11...To view the full article, register now.
Already a subscriber? Click here to view full article